Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$2.07
$0.10(4.59%)
At close: 4:00 PM EDT
$2.07
$0.10(4.59%)
Day’s Range― - ―
52-Week Range$1.61 - $6.88
Previous CloseN/A
Volume336.06K
Average Volume (3M)2.82M
Market Cap
$374.58M
Enterprise Value$801.16
Total Cash (Recent Filing)$194.69M
Total Debt (Recent Filing)$9.79M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Aug 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding180,087,920
10 Day Avg. Volume1,863,301
30 Day Avg. Volume2,817,627
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.17Price Target Upside342.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.44
Revenue Forecast (FY)-$2.22M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseLow reported leverage (debt-to-equity ~0.05) and a meaningful equity base ($186.5M TTM) provide structural financial flexibility for a clinical-stage biotech. This reduces near-term default risk, supports funding of clinical programs, and gives management time to reach regulatory inflection points without immediate insolvency pressure.
Positive Late-stage COMPANION-002 Data And Regulatory PathRobust Phase 2/3 results for tovecimig with materially better PFS and ORR versus control and an explicit regulatory/commercialization plan are durable positives. They materially de‑risk the development path, support eventual market entry planning, and increase the probability that future investment yields commercial revenue over the medium term.
Stronger Governance And Shareholder SupportBylaw updates centralizing Securities Act litigation and recent shareholder votes to elect directors and ratify the auditor improve governance predictability. Clearer forum selection and affirmed board/auditor support reduce legal and oversight uncertainty, helping management focus on long‑term clinical and commercialization programs.
Bears Say
Pre-revenue With Persistent, Sizable Net LossesThe company is effectively pre-revenue and has persistent large net losses (TTM net income -$68.2M). Without recurring product sales, profitability depends on successful clinical and regulatory outcomes; until commercial revenue emerges, the company will structurally rely on external financing to sustain operations.
Worsening Cash Burn And Weak Cash GenerationOperating and free cash flows are deeply negative and have deteriorated over time (OCF -$53.2M TTM versus -$40.6M in 2023), increasing the structural need for external capital. Sustained negative cash generation elevates dilution and financing risk, which can constrain R&D pacing and strategic options over the medium term.
Concentration On Single Lead Clinical AssetBusiness outcomes are highly concentrated on tovecimig's development and regulatory success. As a clinical‑stage company, this creates binary, program‑specific risk: if pivotal development or approval encounters setbacks, revenue prospects and the company's ability to fund other programs would be materially impaired over the medium term.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics, Inc.’s price range in the past 12 months?
Compass Therapeutics, Inc. lowest stock price was $1.61 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics, Inc.’s market cap?
Compass Therapeutics, Inc.’s market cap is $374.58M.
When is Compass Therapeutics, Inc.’s upcoming earnings report date?
Compass Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 6 days.
How were Compass Therapeutics, Inc.’s earnings last quarter?
Compass Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Compass Therapeutics, Inc. overvalued?
According to Wall Street analysts Compass Therapeutics, Inc.’s price is currently Undervalued.
Does Compass Therapeutics, Inc. pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
What is Compass Therapeutics, Inc.’s EPS estimate?
Compass Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Compass Therapeutics, Inc. have?
Compass Therapeutics, Inc. has 180,087,920 shares outstanding.
What happened to Compass Therapeutics, Inc.’s price movement after its last earnings report?
Compass Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went up 0.515%.
Which hedge fund is a major shareholder of Compass Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.17 (342.83% Upside)
$9.17 (342.83% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.08%
Trailing 12-Months
Company Description
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$9.17
▲(342.83% Upside)
Technical Analysis
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.74% Insiders
7.09% Mutual Funds
0.65% Other Institutional Investors
66.77% Public Companies and
Individual Investors